Arginase-1: A new immunohistochemical marker of hepatocytes and hepatocellular neoplasms

American Journal of Surgical Pathology

Volumn 34, Issue 8, 2010, Pages 1147-1154

  Yan, Benjamin C ^a   Gong, Can ^a   Song, Jie ^a   Krausz, Thomas ^a   Tretiakova, Maria ^a   Hyjek, Elizabeth ^a   Al Ahmadie, Hikmat ^b   Alves, Venancio ^c   Xiao, Shu Yuan ^a   Anders, Robert A ^d   Hart, John A ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

arginase; hepatocellular carcinoma; HepPar 1; immunohistochemistry; liver

Indexed keywords

ARGINASE; TUMOR MARKER;

ARTICLE; BRAZIL; CELL DIFFERENTIATION; COMPARATIVE STUDY; ENZYMOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; UNITED STATES;

ARGINASE; BRAZIL; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 77955154380     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181e5dffa     Document Type: Article

References (37)

1. Butler SL, Dong H, Cardona D, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest. 2008;88:78-88.
2. Chrzanowska A, Gajewska B, Baranczyk-Kuzma A. Arginase isoenzymes in human cirrhotic liver. Acta Biochim Pol. 2009;56: 465-469.
3. Chrzanowska A, Krawczyk M, Baranczyk-Kuzma A. Changes in arginase isoenzymes pattern in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2008;377:337-340.
4. Chu PG, Ishizawa S, Wu E, et al. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol. 2002;26:978-988.
5. Chu PG, Weiss LM. Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon. Am J Clin Pathol. 2004;121:884-892.
6. Debats IB, Wolfs TG, Gotoh T, et al. Role of arginine in superficial wound healing in man. Nitric Oxide. 2009;21:175-183.
7. Fan Z, van de Rijn M, Montgomery K, et al. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16:137-144.
8. Fasano M, Theise ND, Nalesnik M, et al. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal anti-carcino-embryonic antigen. Mod Pathol. 1998;11:934-938.
9. Fu X, Tan L, Liu S, et al. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics. J Cancer Res Clin Oncol. 2004;130:514-520.
10. Iczkowski KA, Butler SL. New immunohistochemical markers in testicular tumors. Anal Quant Cytol Histol. 2006;28:181-187.
11. Kakar S, Gown AM, Goodman ZD, et al. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med. 2007;131:1648-1654.
12. Kakar S, Muir T, Murphy LM, et al. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol. 2003;119:361-366.
13. Kohler ES, Sankaranarayanan S, van Ginneken CJ, et al. The human neonatal small intestine has the potential for arginine synthesis; developmental changes in the expression of arginine-synthesizing and-catabolizing enzymes. BMC Dev Biol. 2008;8:107.
14. Lau SK, Prakash S, Geller SA, et al. Comparative immunohisto-chemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002;33:1175-1181.
15. Leong AS, Sormunen RT, Tsui WM, et al. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology. 1998;33:318-324.
16. Maitra A, Murakata LA, Albores-Saavedra J. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract. Am J Clin Pathol. 2001;115:689-694.
17. Minervini MI, Demetris AJ, Lee RG, et al. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol. 1997;10:686-692.
18. Mori M, Gotoh T. Arginine metabolic enzymes, nitric oxide and infection. J Nutr. 2004;134:2820S-2825S; discussion 2853S.
19. Multhaupt H, Fritz P, Schumacher K. Immunohistochemical localisation of arginase in human liver using monoclonal antibodies against human liver arginase. Histochemistry. 1987;87:465-470.
20. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/argi-nase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol. 1998;160:5347-5354.
21. Munder M, Mollinedo F, Calafat J, et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood. 2005;105:2549-2556.
22. Murakata LA, Ishak KG, Nzeako UC. Clear cell carcinoma of the liver: a comparative immunohistochemical study with renal clear cell carcinoma. Mod Pathol. 2000;13:874-881.
23. Ota S, Hishinuma M, Yamauchi N, et al. Oncofetal protein glypican-3 in testicular germ-cell tumor. Virchows Arch. 2006;449:308-314.
24. Ozer J, Ratner M, Shaw M, et al. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245:194-205.
25. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
26. Pauleau AL, Rutschman R, Lang R, et al. Enhancer-mediated control of macrophage-specific arginase I expression. J Immunol. 2004;172:7565-7573.
27. Pesce JT, Ramalingam TR, Mentink-Kane MM, et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog. 2009;5:e1000371.
28. Sekine S, Ogawa R, Mcmanus MT, et al. Dicer is required for proper liver zonation. J Pathol. 2009;219:365-372.
29. Shirakawa H, Kuronuma T, Nishimura Y, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol. 2009;34:649-656.
30. Spector EB, Jenkinson CP, Grigor MR, et al. Subcellular location and differential antibody specificity of arginase in tissue culture and whole animals. Int J Dev Neurosci. 1994;12:337-342.
31. Stempin CC, Dulgerian LR, Garrido VV, et al. Arginase in parasitic infections: macrophage activation, immunosuppression, and intra-cellular signals. J Biomed Biotechnol. 2010;2010:683485.
32. Wakabayashi Y. Tissue-selective expression of enzymes of arginine synthesis. Curr Opin Clin Nutr Metab Care. 1998;1:335-339.
33. Wang HL, Anatelli F, Zhai QJ, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. 2008;132:1723-1728.
34. Wang L, Vuolo M, Suhrland MJ, et al. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma versus metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol. 2006;50:257-262.
35. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol. 1993;143:1050-1054.
36. Zynger DL, Dimov ND, Luan C, et al. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570-1575.
37. Zynger DL, Everton MJ, Dimov ND, et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol. 2008;130:224-230.